Idiopathic multicentric castleman disease imcd

Results 171 to 180 of about 1,385 (194)

Some of the next articles are maybe not open access.

Transcriptomic and pathological insights into PI3K–Akt pathway activation in idiopathic multicentric castleman disease, tafro and NOS subtypes

Blood
Introduction: Idiopathic multicentric Castleman disease (iMCD) is a rare lymphoproliferative disorder characterized by systemic inflammation of unknown etiology.
Tomoka Haratake +10 more
semanticscholar +1 more source

An open-label Phase II trial of VDJ-001, a high-affinity IL-6R antagonist antibody, for the treatment of patients with idiopathic multicentric castleman disease

Blood
Interleukin-6 (IL-6) targeted therapy has been recommended as the most important treatment option for idiopathic Multicentric Castleman Disease (iMCD).
Lu Zhang +7 more
semanticscholar +1 more source

Castleman disease

Nature Reviews Disease Primers, 2021
Antonino Carbone +2 more
exaly

BCD Regimen in Newly Diagnosed Idiopathic Multicentric Castleman's Disease (iMCD)

Case Medical Research, 2019
openaire +1 more source

Overview of Castleman disease

Blood, 2020
Angela Dispenzieri, David C Fajgenbaum
exaly

Castleman's disease—a two compartment model of HHV8 infection

Nature Reviews Clinical Oncology, 2010
Klaus-Martin Schulte
exaly

Idiopathic multicentric Castleman's disease: a systematic literature review

Lancet Haematology,the, 2016
Amy Y Liu +2 more
exaly

Prospective Study of Rituximab in Chemotherapy-Dependent Human Immunodeficiency Virus–Associated Multicentric Castleman's Disease: ANRS 117 CastlemaB Trial

Journal of Clinical Oncology, 2007
Laurence Gérard, Renaud Verdon, Eric Oksenhendler +2 more
exaly